Logo image of PRGO

PERRIGO CO PLC (PRGO) Stock Fundamental Analysis

USA - NYSE:PRGO - IE00BGH1M568 - Common Stock

21.93 USD
+0.23 (+1.06%)
Last: 10/21/2025, 8:04:00 PM
21.93 USD
0 (0%)
After Hours: 10/21/2025, 8:04:00 PM
Fundamental Rating

5

PRGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of PRGO while its profitability can be described as average. PRGO is valued quite cheap, while showing a decent growth score. This is a good combination! PRGO also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year PRGO was profitable.
In the past year PRGO had a positive cash flow from operations.
In the past 5 years PRGO always reported negative net income.
In the past 5 years PRGO always reported a positive cash flow from operatings.
PRGO Yearly Net Income VS EBIT VS OCF VS FCFPRGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

Looking at the Return On Assets, with a value of -0.80%, PRGO is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.80%, PRGO is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
With an excellent Return On Invested Capital value of 3.64%, PRGO belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
PRGO had an Average Return On Invested Capital over the past 3 years of 2.21%. This is significantly below the industry average of 15.45%.
The last Return On Invested Capital (3.64%) for PRGO is above the 3 year average (2.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.8%
ROE -1.8%
ROIC 3.64%
ROA(3y)-1.06%
ROA(5y)-1.05%
ROE(3y)-2.38%
ROE(5y)-2.27%
ROIC(3y)2.21%
ROIC(5y)2.9%
PRGO Yearly ROA, ROE, ROICPRGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

Looking at the Operating Margin, with a value of 9.55%, PRGO belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
PRGO's Operating Margin has improved in the last couple of years.
PRGO has a Gross Margin of 35.73%. This is comparable to the rest of the industry: PRGO outperforms 59.69% of its industry peers.
In the last couple of years the Gross Margin of PRGO has remained more or less at the same level.
Industry RankSector Rank
OM 9.55%
PM (TTM) N/A
GM 35.73%
OM growth 3Y-22.79%
OM growth 5Y3.71%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.98%
PRGO Yearly Profit, Operating, Gross MarginsPRGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

3

2. Health

2.1 Basic Checks

PRGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PRGO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRGO has been increased compared to 5 years ago.
Compared to 1 year ago, PRGO has an improved debt to assets ratio.
PRGO Yearly Shares OutstandingPRGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
PRGO Yearly Total Debt VS Total AssetsPRGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of 0.74, we must say that PRGO is in the distress zone and has some risk of bankruptcy.
PRGO has a Altman-Z score (0.74) which is in line with its industry peers.
The Debt to FCF ratio of PRGO is 14.23, which is on the high side as it means it would take PRGO, 14.23 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 14.23, PRGO is doing good in the industry, outperforming 77.49% of the companies in the same industry.
PRGO has a Debt/Equity ratio of 0.81. This is a neutral value indicating PRGO is somewhat dependend on debt financing.
The Debt to Equity ratio of PRGO (0.81) is worse than 71.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 14.23
Altman-Z 0.74
ROIC/WACC0.46
WACC7.92%
PRGO Yearly LT Debt VS Equity VS FCFPRGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 2.32 indicates that PRGO has no problem at all paying its short term obligations.
The Current ratio of PRGO (2.32) is comparable to the rest of the industry.
PRGO has a Quick Ratio of 1.24. This is a normal value and indicates that PRGO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.24, PRGO is doing worse than 69.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.24
PRGO Yearly Current Assets VS Current LiabilitesPRGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

4

3. Growth

3.1 Past

PRGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.43%, which is quite impressive.
PRGO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -8.68% yearly.
PRGO shows a decrease in Revenue. In the last year, the revenue decreased by -2.31%.
Measured over the past years, PRGO shows a small growth in Revenue. The Revenue has been growing by 2.48% on average per year.
EPS 1Y (TTM)25.43%
EPS 3Y7.69%
EPS 5Y-8.68%
EPS Q2Q%7.55%
Revenue 1Y (TTM)-2.31%
Revenue growth 3Y1.86%
Revenue growth 5Y2.48%
Sales Q2Q%-0.86%

3.2 Future

PRGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.85% yearly.
The Revenue is expected to grow by 1.28% on average over the next years.
EPS Next Y19.13%
EPS Next 2Y11.75%
EPS Next 3Y10.46%
EPS Next 5Y8.85%
Revenue Next Year-1.04%
Revenue Next 2Y-0.25%
Revenue Next 3Y0.51%
Revenue Next 5Y1.28%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PRGO Yearly Revenue VS EstimatesPRGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B 5B
PRGO Yearly EPS VS EstimatesPRGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.54, the valuation of PRGO can be described as very cheap.
Based on the Price/Earnings ratio, PRGO is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PRGO to the average of the S&P500 Index (27.77), we can say PRGO is valued rather cheaply.
A Price/Forward Earnings ratio of 6.86 indicates a rather cheap valuation of PRGO.
Based on the Price/Forward Earnings ratio, PRGO is valued cheaper than 92.67% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, PRGO is valued rather cheaply.
Industry RankSector Rank
PE 7.54
Fwd PE 6.86
PRGO Price Earnings VS Forward Price EarningsPRGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PRGO is valued cheaply inside the industry as 91.10% of the companies are valued more expensively.
PRGO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PRGO is cheaper than 89.01% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.75
EV/EBITDA 8.33
PRGO Per share dataPRGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

PRGO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PRGO may justify a higher PE ratio.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y11.75%
EPS Next 3Y10.46%

7

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.39%, PRGO is a good candidate for dividend investing.
The stock price of PRGO dropped by -22.86% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 6.88, PRGO pays a better dividend. On top of this PRGO pays more dividend than 97.91% of the companies listed in the same industry.
PRGO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 5.39%

5.2 History

The dividend of PRGO is nicely growing with an annual growth rate of 6.29%!
PRGO has paid a dividend for at least 10 years, which is a reliable track record.
PRGO has decreased its dividend recently.
Dividend Growth(5Y)6.29%
Div Incr Years1
Div Non Decr Years1
PRGO Yearly Dividends per sharePRGO Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

PRGO has negative earnings and hence a negative payout ratio. The dividend may be in danger.
PRGO's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-195.14%
EPS Next 2Y11.75%
EPS Next 3Y10.46%
PRGO Yearly Income VS Free CF VS DividendPRGO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

PERRIGO CO PLC

NYSE:PRGO (10/21/2025, 8:04:00 PM)

After market: 21.93 0 (0%)

21.93

+0.23 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners105.83%
Inst Owner Change-0.12%
Ins Owners0.45%
Ins Owner Change7.9%
Market Cap3.02B
Analysts78
Price Target34.17 (55.81%)
Short Float %5.19%
Short Ratio3.99
Dividend
Industry RankSector Rank
Dividend Yield 5.39%
Yearly Dividend1.12
Dividend Growth(5Y)6.29%
DP-195.14%
Div Incr Years1
Div Non Decr Years1
Ex-Date08-29 2025-08-29 (0.29)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.81%
Min EPS beat(2)-5.82%
Max EPS beat(2)7.44%
EPS beat(4)1
Avg EPS beat(4)-0.48%
Min EPS beat(4)-5.82%
Max EPS beat(4)7.44%
EPS beat(8)5
Avg EPS beat(8)4.63%
EPS beat(12)8
Avg EPS beat(12)4.32%
EPS beat(16)9
Avg EPS beat(16)-0.21%
Revenue beat(2)0
Avg Revenue beat(2)-5.05%
Min Revenue beat(2)-5.79%
Max Revenue beat(2)-4.32%
Revenue beat(4)0
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-6.62%
Max Revenue beat(4)-4.32%
Revenue beat(8)0
Avg Revenue beat(8)-5.42%
Revenue beat(12)0
Avg Revenue beat(12)-4.72%
Revenue beat(16)1
Avg Revenue beat(16)-3.62%
PT rev (1m)0%
PT rev (3m)-8.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.39%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-1.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.93%
Valuation
Industry RankSector Rank
PE 7.54
Fwd PE 6.86
P/S 0.7
P/FCF 11.75
P/OCF 8.24
P/B 0.67
P/tB N/A
EV/EBITDA 8.33
EPS(TTM)2.91
EY13.27%
EPS(NY)3.2
Fwd EY14.58%
FCF(TTM)1.87
FCFY8.51%
OCF(TTM)2.66
OCFY12.14%
SpS31.44
BVpS32.51
TBVpS-11.41
PEG (NY)0.39
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.8%
ROE -1.8%
ROCE 4.61%
ROIC 3.64%
ROICexc 3.83%
ROICexgc 13.21%
OM 9.55%
PM (TTM) N/A
GM 35.73%
FCFM 5.93%
ROA(3y)-1.06%
ROA(5y)-1.05%
ROE(3y)-2.38%
ROE(5y)-2.27%
ROIC(3y)2.21%
ROIC(5y)2.9%
ROICexc(3y)2.37%
ROICexc(5y)3.33%
ROICexgc(3y)9.14%
ROICexgc(5y)12.63%
ROCE(3y)2.79%
ROCE(5y)3.67%
ROICexcg growth 3Y-27.17%
ROICexcg growth 5Y8.08%
ROICexc growth 3Y-25.01%
ROICexc growth 5Y10.11%
OM growth 3Y-22.79%
OM growth 5Y3.71%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.98%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 14.23
Debt/EBITDA 4.87
Cap/Depr 33.3%
Cap/Sales 2.53%
Interest Coverage 250
Cash Conversion 49.35%
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.24
Altman-Z 0.74
F-Score5
WACC7.92%
ROIC/WACC0.46
Cap/Depr(3y)31.02%
Cap/Depr(5y)43.56%
Cap/Sales(3y)2.35%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.43%
EPS 3Y7.69%
EPS 5Y-8.68%
EPS Q2Q%7.55%
EPS Next Y19.13%
EPS Next 2Y11.75%
EPS Next 3Y10.46%
EPS Next 5Y8.85%
Revenue 1Y (TTM)-2.31%
Revenue growth 3Y1.86%
Revenue growth 5Y2.48%
Sales Q2Q%-0.86%
Revenue Next Year-1.04%
Revenue Next 2Y-0.25%
Revenue Next 3Y0.51%
Revenue Next 5Y1.28%
EBIT growth 1Y104.45%
EBIT growth 3Y-21.35%
EBIT growth 5Y6.28%
EBIT Next Year40.12%
EBIT Next 3Y15.03%
EBIT Next 5Y10.05%
FCF growth 1Y8.54%
FCF growth 3YN/A
FCF growth 5Y19.35%
OCF growth 1Y15.37%
OCF growth 3Y32.42%
OCF growth 5Y-1.32%